10-Fold increase (2006-11) in the rate of healthy subjects with extended-spectrum β-lactamase-producing Escherichia coli faecal carriage in a Parisian check-up centre
Objectives In 2006, 0.6% of healthy subjects living in the Paris area had extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in their gut. To assess the evolution of this rate, a study identical to that of 2006 was conducted in 2011. Participants and methods Healthy adults who visited the IPC check-up centre in February–March 2011 and agreed to participate, provided stools and answered a questionnaire on the visit day. Stools were analysed to detect ESBL producers and to isolate the dominant E. coli population. ESBLs were molecularly characterised. For the subjects harbouring ESBL-producing E. coli, the phylogenetic group and sequence type (ST) were determined
for both ESBL-producing and dominant E. coli isolates. PFGE profiles were also determined when two
types of isolates had the same ST. Results Among the 345 subjects included, 21 (6%) had ESBL-producing E. coli faecal carriage. None of the previously published risk factors was identified. CTX-M accounted for 86% and SHV-12 for 14%. Dominant and ESBL-producing E. coli were similarly distributed into phylogenetic groups (A, 52%–48%; B1, 5%; B2, 24%–14%; and D, 19%–33%). Dominant and ESBL-producing E. coli displayed a polyclonal structure (18 STs each). However, ST10 and ST131 were identified in dominant and ESBL-producing E. coli isolates from different subjects. Most (20/21) ESBL producers were subdominant and belonged (16/21) to STs different from that of the corresponding dominant E. coli. Conclusions The 10-fold increase in the rate of healthy subjects with ESBL-producing E. coli faecal carriage over a 5-year period suggests wide dissemination of these isolates in the Parisian community.
Citation: J Antimicrob Chemother. 2013 Mar;68(3):562-8. doi: 10.1093/jac/dks429. Epub 2012 Nov 9.
Publication Type: Journal article
Publisher: Journal of Antimicrobial Chemotherapy